TrialBMC infectious diseases2025

Influence of anti-Spike protein antibody levels on tocilizumab efficacy in hospitalized patients with severe COVID-19 pneumonia: a post-hoc analysis of the COVACTA trial.

José Aguareles et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.